Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
Want to see AU:PIQ full AI Analyst Report?
Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.14
▼(-78.51% Downside)
Action:Reiterated
Date:05/12/26
The score is primarily weighed down by weak financial performance (sharp revenue contraction, ongoing losses, and negative operating/free cash flow). Technical indicators also remain bearish with the price below major moving averages and negative MACD, while valuation is difficult to assess due to negative earnings and no provided dividend yield.
Positive Factors
Diversified revenue streams
Proteomics International generates revenue from both diagnostics (commercial tests) and contract proteomics services. This two‑pronged model provides durable revenue diversification, allowing service fees to partly offset variability in diagnostic adoption and supporting operational continuity over multiple quarters.
Negative Factors
Steep revenue decline
A reported -72.53% revenue decline signals a major loss of scale and customer traction. Sustained top-line contraction undermines unit economics, reduces negotiating leverage with partners and payors, and constrains the company's ability to fund commercialization and validation activities over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
Proteomics International generates revenue from both diagnostics (commercial tests) and contract proteomics services. This two‑pronged model provides durable revenue diversification, allowing service fees to partly offset variability in diagnostic adoption and supporting operational continuity over multiple quarters.
Read all positive factors
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$22.30M
Dividend YieldN/A
Average Volume (3M)426.90K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue Growth-23.71%
EPS Growth-16.02%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding165,184,000
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$4.30M
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Company Description
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis a...
How the Company Makes Money
PIQ makes money through two primary revenue streams: (1) Diagnostics—income generated from the commercialization and delivery of its proteomics-based diagnostic tests (e.g., per-test/service revenue from laboratories, healthcare providers, or chan...
Proteomics International Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 480.45K | 960.39K | 892.14K | 730.34K | 1.49M | 1.31M |
| Gross Profit | -9.26M | 960.39K | -1.12M | -1.62M | -568.62K | 497.08K |
| EBITDA | -11.94M | -10.00M | -8.40M | -7.55M | -4.56M | -2.77M |
| Net Income | -9.66M | -8.11M | -6.38M | -6.23M | -4.97M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 11.30M | 14.78M | 10.88M | 10.08M | 5.40M | 8.60M |
| Cash, Cash Equivalents and Short-Term Investments | 7.67M | 11.04M | 6.64M | 6.03M | 2.11M | 5.60M |
| Total Debt | 681.45K | 277.74K | 316.39K | 64.09K | 0.00 | 69.05K |
| Total Liabilities | 4.09M | 1.81M | 1.63M | 1.75M | 2.00M | 990.19K |
| Stockholders Equity | 7.45M | 13.17M | 9.41M | 8.38M | 3.39M | 7.61M |
Cash Flow | ||||||
| Free Cash Flow | -8.41M | -6.63M | -6.00M | -6.91M | -3.67M | -2.41M |
| Operating Cash Flow | -6.35M | -6.60M | -5.59M | -5.69M | -3.54M | -2.21M |
| Investing Cash Flow | -2.07M | -29.65K | -388.02K | -1.17M | -129.46K | -191.00K |
| Financing Cash Flow | 10.76M | 11.03M | 6.59M | 10.77M | 176.10K | 5.64M |
Proteomics International Laboratories Ltd. Technical Analysis
Negative
0.67
Price Trends
0.22
Negative
0.35
Negative
0.37
Negative
Market Momentum
-0.03
Negative
32.96
Neutral
8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PIQ, the sentiment is Negative. The current price of 0.67 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.22, and above the 200-day MA of 0.37, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 32.96 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PIQ.
Proteomics International Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$70.88M | -1.58 | -93.08% | ― | 116.02% | 75.56% | |
52 Neutral | AU$82.02M | -8.83 | -62.49% | ― | ― | -13.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$5.32M | -0.22 | 2844.96% | ― | ― | 62.07% | |
42 Neutral | AU$22.30M | -2.29 | -93.66% | ― | -23.71% | -16.02% | |
42 Neutral | AU$46.27M | -1.66 | -254.33% | ― | ― | 5.16% | |
41 Neutral | AU$159.05M | -5.26 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:PIQ
Proteomics International Laboratories Ltd.
0.14
-0.29
-67.86%
AU:PTX
Prescient Therapeutics Limited
0.08
0.03
65.96%
AU:NUZ
Pharmaust Limited
0.06
-0.08
-54.74%
AU:CHM
Chimeric Therapeutics Ltd.
0.10
-0.07
-41.18%
AU:RAD
Radiopharm Theranostics Limited
0.02
>-0.01
-28.57%
AU:RCE
Recce Pharmaceuticals Ltd.
0.55
0.21
59.42%
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International says no undisclosed news behind share price moves
May 7, 2026
Proteomics International Laboratories has told the ASX it is unaware of any undisclosed information that would explain recent trading in its shares, pointing instead to a series of market-sensitive updates released in late April. These included it...
Proteomics International Warns Investors of Imminent Option Expiry
May 1, 2026
Proteomics International Laboratories has notified holders of its listed options that these securities, exercisable at $0.50, will expire at 5:00pm AEST on 31 May 2026, with ASX quotation to cease on 25 May. Option holders may exercise their optio...
Proteomics International Resets Strategy to Drive Commercial Diagnostics Growth
Apr 27, 2026
Proteomics International Laboratories has completed a strategic review and begun transforming from a predominantly research-driven organisation into a commercially focused diagnostics business. The company plans to leverage its proteomics expertis...
Proteomics International Maps Shift From Research to Commercial Focus
Apr 27, 2026
Proteomics International Laboratories is outlining its strategy to move from a research-centric organisation to a commercially focused diagnostics and proteomics services business. The company emphasises that the material presented is informationa...
Proteomics International Announces Departure of Director Neville Gardiner
Apr 17, 2026
Proteomics International Laboratories has announced that non-executive director Neville Gardiner has ceased to be a director of the company as of 16 April 2026. Gardiner holds no securities directly but retains indirect interests through the Gardi...
Proteomics International Restructures as It Accelerates Commercial Diagnostics Focus
Apr 16, 2026
Proteomics International Laboratories has undertaken an organisational restructure as it shifts from a predominantly research-driven operation to a commercially focused diagnostics company. The company specialises in proteomics-based precision dia...
Proteomics International Widens Half-Year Loss as Revenue Declines
Feb 24, 2026
Proteomics International Laboratories reported a weak first half for the six months to 31 December 2025, with operating and other activity revenues falling 30% to $357,000 and total income including grants and other revenue declining 10% to $868,7...
Proteomics International Founder Dr Richard Lipscombe Retires from Board
Feb 23, 2026
Proteomics International Laboratories Ltd announced the formal retirement of founder and Managing Director Dr Richard Lipscombe from its board of directors, effective 23 February 2026, after 25 years of leadership. His departure marks the end of a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.